The American Journal of Managed Care1h
Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
‘Annual shot to prevent HIV proven safe’
The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...
News-Medical.Net on MSN11h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
GlobalData on MSN10h
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
BioSpace9h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
The Financial Express11h
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
The American Journal of Managed Care4h
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and ...
India Today on MSN17h
Bitten by a dog? Rabies vaccine is not enough, you need more to stay safe
Even a minor scratch from a potentially rabid animal requires immediate medical attention. According to Dr. Neha Rastogi Panda, Consultant-Infectious Diseases at Fortis Memorial Research Institute, ...
Yearly Injection To Protect Against HIV? Gilead's Lenacapavir Shows Promise In Clinical Trial
A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...
The Washington Informer6h
Empowering Women and Girls: Advancing HIV Prevention
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...